within Pharmacolibrary.Drugs.ATC.M;

model M01AB55
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.53,
    Cl             = 0.0055000000000000005,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 900,            
    Vdp             = 0.008,
    k12             = 12,
    k21             = 12
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AB55</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammatory disorders such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The 'combinations' formulation refers to diclofenac used in combination with other agents, most commonly with misoprostol to reduce gastric side effects, or with other analgesics for enhanced efficacy. Diclofenac combinations are commonly approved and still in clinical use today.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for healthy adult subjects receiving oral diclofenac in combination products.</p><h4>References</h4><ol><li><p>Altman, R, et al., &amp; Young, C (2015). Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. <i>Drugs</i> 75(8) 859–877. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0392-z\">10.1007/s40265-015-0392-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25963327/\">https://pubmed.ncbi.nlm.nih.gov/25963327</a></p></li><li><p>Moreira, SA, &amp; Liu, DJ (2017). Diclofenac systemic bioavailability of a topical 1% diclofenac + 3% menthol combination gel vs. an oral diclofenac tablet in healthy volunteers: a randomized, open-label, crossover study . <i>International journal of clinical pharmacology and therapeutics</i> 55(4) 368–372. DOI:<a href=\"https://doi.org/10.5414/CP202753\">10.5414/CP202753</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27936526/\">https://pubmed.ncbi.nlm.nih.gov/27936526</a></p></li><li><p>Kim, TH, et al., &amp; Shin, BS (2018). Pharmacokinetics and Anti-Gastric Ulceration Activity of Oral Administration of Aceclofenac and Esomeprazole in Rats. <i>Pharmaceutics</i> 10(3) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics10030152\">10.3390/pharmaceutics10030152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30200587/\">https://pubmed.ncbi.nlm.nih.gov/30200587</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AB55;
